Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study
Clicks: 255
ID: 8066
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
63.7
/100
255 views
204 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study| Reference Key |
wu2019entecavirinfection
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Xiaoning Wu;Jialing Zhou;Wen Xie;Huiguo Ding;Xiaojuan Ou;Guofeng Chen;Anlin Ma;Xiaoyuan Xu;Hui Ma;Youqing Xu;Xiaoqing Liu;Tongtong Meng;Lin Wang;Yameng Sun;Bingqiong Wang;Yuanyuan Kong;Hong Ma;Hong You;Jidong Jia; |
| Journal | Infection and drug resistance |
| Year | 2019 |
| DOI | 10.2147/IDR.S185120 |
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.